Shots:

• The approval is based on KEYNOTE-158 & KEYNOTE-028 studies result assessing Keytruda (200mg- IV) in patients with SCLC with disease progression on/after platinum-based CT- prior treated with 1L+ therapy
• Collective results: ORR (19%); CRR (2%); PRR (17%); DOR @6mos. (94%); DOR @12mos. (63%); DOR @18mos. (56%)
• Keytruda is an anti-PD-1 therapy- blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thereby activating T lymphocytes- affecting both tumor & healthy cells- being evaluated in 1000+ studies for multiple cancer

Ref: Merck | Image: Merck